drugset
drugset / Trial / NCT03226210

Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

NCT03226210 ↗

Phase 4 Completed 110 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare the effect of the rapid-acting insulin analogues (RAIAs) NovoRapid (aspart) and Prandilin (lispro) on glycemic variations by Continuous glucose monitoring system (CGMS) in continuous subcutaneous insulin infusion (CSII) with metformin intensive therapy in newly diagnosed type 2 diabetes mellitus (T2DM).

Timeline

Start
2015-02-01
Primary completion
2016-05-01
Completion
2016-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic — Subcutaneous
Subject lipro insulin Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus